Nasim Tootoonchi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Nasim Tootoonchi has a total of 66 co-authors. Here are the top co-authors by number of shared publications:
- Mahshid Sadat Ansari
Department of Dermatology, Razi Hospital, Tehran University of Medical Sciences, Tehran, Iran
4 shared publications Kamran Balighi
Autoimmune Bullous Diseases Research Center, Razi Hospital Tehran University of Medical Sciences Tehran Iran
3 shared publications- Kamran Balighi
Autoimmune Bullous Diseases Research Center Tehran University of Medical Sciences Tehran Iran
3 shared publications Maryam Nasimi
Department of Dermatology, Razi Hospital Tehran University of Medical Sciences Tehran Iran
3 shared publications- Maryam Nasimi
Department of Dermatology, Razi Hospital, Tehran University of Medical Sciences, Tehran, Iran
3 shared publications - Parvaneh Hatami
Department of Dermatology, Autoimmune Bullous Diseases Research Center, Tehran University of Medical Sciences, Tehran, Iran
3 shared publications
Latest Publications
- Open Access
- 30 July 2025
- Published by Wiley in Journal of Cosmetic Dermatology
- Vol. 24 (8) , e70367
Is Intralesional Methotrexate an Effective Alternative to Intralesional Triamcinolone in Alopecia Areata? Findings From a Randomized Controlled Trial
Background: Alopecia areata (AA) is an autoimmune condition resulting in hair loss, sometimes just in small patches but occasionally across larger areas like the entire scalp. For localized AA, treatments often involve injecting corticosteroids, such as triamcinolone acetonide (TrA), directly into the affected areas. Methotrexate (MTX), a drug known for its ability to suppress immune responses, has also been considered as an alternative. However, there has not been much research directly comparing these two treatments.Methods: This study involved 40 individuals with localized AA. These patients were divided into two groups: one received TrA injections, and the other was given MTX. Both groups were treated once a month for 3 months. We tracked their progress using the Severity of Alopecia Tool (SALT) over 6 months. Their trichoscopic findings, adverse effects, and satisfaction with treatment were also documented.Results: Cases receiving TrA showed strong improvements, with their SALT scores dropping by an average of 54.36%, which meant significant hair regrowth. In contrast, the MTX group saw their scores worsen by 54.6%, meaning losing more hair. For trichoscopic changes, both groups showed some progress, but only the reduction in black dots in the MTX group was statistically significant. Side effects like mild redness or pigmentation changes were uncommon and similar for both groups. When asked how satisfied they were, patients who received TrA gave a much higher score:7.1 out of 10 compared to 4.9 for MTX.Discussion: According to our results, TrA outperformed MTX in treating localized AA, both in terms of hair regrowth and patient satisfaction. While MTX may have potential as a therapy, its inconsistent performance in this study suggests it is not ready to be a primary option for localized AA. Future research is needed to explore whether adjusting doses or combining it with other treatments could result in better outcomes.
- 30 July 2025
- Published by Wiley in Journal of Cosmetic Dermatology
- Vol. 24 (8) , e70367
Open AccessIs Intralesional Methotrexate an Effective Alternative to Intralesional Triamcinolone in Alopecia Areata? Findings From a Randomized Controlled Trial
Background: Alopecia areata (AA) is an autoimmune condition resulting in hair loss, sometimes just in small patches but occasionally across larger areas like the entire scalp. For localized AA, treatments often involve injecting corticosteroids, such as triamcinolone acetonide (TrA), directly into the affected areas. Methotrexate (MTX), a drug known for its ability to suppress immune responses, has also been considered as an alternative. However, there has not been much research directly comparing these two treatments.Methods: This study involved 40 individuals with localized AA. These patients were divided into two groups: one received TrA injections, and the other was given MTX. Both groups were treated once a month for 3 months. We tracked their progress using the Severity of Alopecia Tool (SALT) over 6 months. Their trichoscopic findings, adverse effects, and satisfaction with treatment were also documented.Results: Cases receiving TrA showed strong improvements, with their SALT scores dropping by an average of 54.36%, which meant significant hair regrowth. In contrast, the MTX group saw their scores worsen by 54.6%, meaning losing more hair. For trichoscopic changes, both groups showed some progress, but only the reduction in black dots in the MTX group was statistically significant. Side effects like mild redness or pigmentation changes were uncommon and similar for both groups. When asked how satisfied they were, patients who received TrA gave a much higher score:7.1 out of 10 compared to 4.9 for MTX.Discussion: According to our results, TrA outperformed MTX in treating localized AA, both in terms of hair regrowth and patient satisfaction. While MTX may have potential as a therapy, its inconsistent performance in this study suggests it is not ready to be a primary option for localized AA. Future research is needed to explore whether adjusting doses or combining it with other treatments could result in better outcomes.
- 17 February 2025
- Published by Taylor & Francis in Journal of Cosmetic and Laser Therapy
- Vol. 27 (1-2) , 31-38
Role of pulsed dye laser in treating basal cell carcinoma: a review of articles
Basal cell carcinoma (BCC) is the most prevalent skin cancer, belonging to a group of skin cancers, namely Non-melanoma skin cancers. The increasing annual incidence, cosmetic disfigurements, and high recurrence rates give prominence to the role of the treatment methods used. Although there are numerous treatment modalities, pulsed dye laser (PDL) has emerged as an effective treatment for basal cell carcinoma in recent years. In this review, we aimed to assess the efficacy of pulsed dye laser on basal cell carcinoma in previous studies.
- 17 February 2025
- Published by Taylor & Francis in Journal of Cosmetic and Laser Therapy
- Vol. 27 (1-2) , 31-38
Role of pulsed dye laser in treating basal cell carcinoma: a review of articles
Basal cell carcinoma (BCC) is the most prevalent skin cancer, belonging to a group of skin cancers, namely Non-melanoma skin cancers. The increasing annual incidence, cosmetic disfigurements, and high recurrence rates give prominence to the role of the treatment methods used. Although there are numerous treatment modalities, pulsed dye laser (PDL) has emerged as an effective treatment for basal cell carcinoma in recent years. In this review, we aimed to assess the efficacy of pulsed dye laser on basal cell carcinoma in previous studies.
- Open Access
- 8 January 2025
- Published by Oxford University Press (OUP) in Aesthetic Surgery Journal Open Forum
- Vol. 7
Ultrasound-Guided Hyaluronidase Injections for the Management of Filler-Induced Arterial Ischemia: A Pictorial Case Series and Systematic Review of Literature
The use of fillers for cosmetic purposes has increased in recent years. Although generally considered safe, fillers are not exempt from complications, including ischemic events. Arterial ischemia is a rare but potentially serious complication that requires prompt recognition and management. Ultrasound-guided hyaluronidase injection is emerging as a precise and effective treatment approach. The authors present a pictorial case series of filler-induced arterial ischemia managed with ultrasound-guided hyaluronidase injections, and systematically review the literature on ultrasound findings, enzyme dosage, time to resolution, and overall effectiveness of this approach. They present 3 cases of filler-induced arterial ischemia in the frontal, nasal, and temporal regions with visible intravascular thrombosis managed with ultrasound-guided intravascular hyaluronidase injections. Additionally, the authors systematically reviewed literature from PubMed/Medline, Scopus, Embase, and Web of Science up to August 2024 to evaluate the effectiveness, dosage, and ultrasound techniques utilized in the ultrasound-guided treatment of vascular complications from hyaluronic acid fillers. Following Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines, we screened 88 studies, finally including 9 studies after full-text evaluation. Data from these studies, alongside our 3 cases (totaling 83 cases), showed rapid resolution of symptoms and ultrasound abnormalities following ultrasound-guided hyaluronidase injections. Delayed hyaluronidase administration was associated with slower or incomplete recovery, highlighting the importance of early intervention. Ultrasound-guided hyaluronidase injections effectively resolve arterial ischemia caused by filler injections, with early intervention significantly enhancing outcomes. Prompt diagnosis and timely ultrasound-guided intervention should be emphasized in clinical practice. Further large-scale randomized studies are necessary to establish standardized treatment protocols for dosage and timing. Level of Evidence: 3 (Therapeutic)
- 8 January 2025
- Published by Oxford University Press (OUP) in Aesthetic Surgery Journal Open Forum
- Vol. 7
Open AccessUltrasound-Guided Hyaluronidase Injections for the Management of Filler-Induced Arterial Ischemia: A Pictorial Case Series and Systematic Review of Literature
The use of fillers for cosmetic purposes has increased in recent years. Although generally considered safe, fillers are not exempt from complications, including ischemic events. Arterial ischemia is a rare but potentially serious complication that requires prompt recognition and management. Ultrasound-guided hyaluronidase injection is emerging as a precise and effective treatment approach. The authors present a pictorial case series of filler-induced arterial ischemia managed with ultrasound-guided hyaluronidase injections, and systematically review the literature on ultrasound findings, enzyme dosage, time to resolution, and overall effectiveness of this approach. They present 3 cases of filler-induced arterial ischemia in the frontal, nasal, and temporal regions with visible intravascular thrombosis managed with ultrasound-guided intravascular hyaluronidase injections. Additionally, the authors systematically reviewed literature from PubMed/Medline, Scopus, Embase, and Web of Science up to August 2024 to evaluate the effectiveness, dosage, and ultrasound techniques utilized in the ultrasound-guided treatment of vascular complications from hyaluronic acid fillers. Following Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines, we screened 88 studies, finally including 9 studies after full-text evaluation. Data from these studies, alongside our 3 cases (totaling 83 cases), showed rapid resolution of symptoms and ultrasound abnormalities following ultrasound-guided hyaluronidase injections. Delayed hyaluronidase administration was associated with slower or incomplete recovery, highlighting the importance of early intervention. Ultrasound-guided hyaluronidase injections effectively resolve arterial ischemia caused by filler injections, with early intervention significantly enhancing outcomes. Prompt diagnosis and timely ultrasound-guided intervention should be emphasized in clinical practice. Further large-scale randomized studies are necessary to establish standardized treatment protocols for dosage and timing. Level of Evidence: 3 (Therapeutic)
- Open Access
- 1 January 2025
- Published by Wiley in Dermatologic Therapy
- Vol. 2025 (1)
Clinical, Histopathological, and Direct Immunofluorescence Characteristics of Prurigo‐Nodularis‐Like Lesions and Pruritus: A Retrospective Study of Patients Admitted to a Tertiary Dermatology Hospital
Background: Prurigo nodularis (PN) is a chronic skin condition characterized by intensely itchy nodules. Accurate identification and treatment of PN‐like lesions are crucial due to their association with various dermatoses. Direct immunofluorescence (DIF) assays play a significant role in distinguishing PN from similar conditions. Methods: We conducted a retrospective analysis on patients referred to a tertiary dermatology hospital between 2017 and 2022. These patients presented with pruritus and PN‐like lesions and underwent skin biopsies. PN diagnosis relied on clinical evidence, laboratory results, and histopathology, ruling out other differentials. Collected data included demographics, clinical manifestations, histology, and final diagnoses. Statistical analysis employed SPSS Version 26, using mean, standard deviation, frequency, and percentage. Significance was set at p < 0.05. Results: Our study included 746 individuals (mean age 45.34 ± 22.05; 423 females and 323 males) with pruritus and PN‐like lesions. Clinical evidence and laboratory findings established final diagnoses: PN (51.1%), dermatitis (17.6%), lichen planus (8.4%), perforating disease (7.0%), and bite reaction (3.1%). DIF assays were performed on 177 patients, with 26 (19.2%) yielding positive results. Bullous pemphigoid (50%) and dermatitis herpetiformis (11.5%) were the most common diagnoses. Conclusion: Our study emphasizes the need for comprehensive diagnostic approaches, including DIF, to accurately diagnose PN‐related conditions. The high PN confirmation rate validates initial clinical suspicion and expert judgment. Considering the potential confusion with dermatitis and immunobullous disorders, targeted health policies and resource allocation are essential for improved diagnostic capabilities and treatment outcomes in patients with PN‐like lesions.
- 1 January 2025
- Published by Wiley in Dermatologic Therapy
- Vol. 2025 (1)
Open AccessClinical, Histopathological, and Direct Immunofluorescence Characteristics of Prurigo‐Nodularis‐Like Lesions and Pruritus: A Retrospective Study of Patients Admitted to a Tertiary Dermatology Hospital
Background: Prurigo nodularis (PN) is a chronic skin condition characterized by intensely itchy nodules. Accurate identification and treatment of PN‐like lesions are crucial due to their association with various dermatoses. Direct immunofluorescence (DIF) assays play a significant role in distinguishing PN from similar conditions. Methods: We conducted a retrospective analysis on patients referred to a tertiary dermatology hospital between 2017 and 2022. These patients presented with pruritus and PN‐like lesions and underwent skin biopsies. PN diagnosis relied on clinical evidence, laboratory results, and histopathology, ruling out other differentials. Collected data included demographics, clinical manifestations, histology, and final diagnoses. Statistical analysis employed SPSS Version 26, using mean, standard deviation, frequency, and percentage. Significance was set at p < 0.05. Results: Our study included 746 individuals (mean age 45.34 ± 22.05; 423 females and 323 males) with pruritus and PN‐like lesions. Clinical evidence and laboratory findings established final diagnoses: PN (51.1%), dermatitis (17.6%), lichen planus (8.4%), perforating disease (7.0%), and bite reaction (3.1%). DIF assays were performed on 177 patients, with 26 (19.2%) yielding positive results. Bullous pemphigoid (50%) and dermatitis herpetiformis (11.5%) were the most common diagnoses. Conclusion: Our study emphasizes the need for comprehensive diagnostic approaches, including DIF, to accurately diagnose PN‐related conditions. The high PN confirmation rate validates initial clinical suspicion and expert judgment. Considering the potential confusion with dermatitis and immunobullous disorders, targeted health policies and resource allocation are essential for improved diagnostic capabilities and treatment outcomes in patients with PN‐like lesions.
- Open Access
- 16 February 2024
- Published by Wiley in Journal of Cosmetic Dermatology
- Vol. 23 (6) , 2090-2096
Comparison of efficacy and safety of tretinoin 0.05% and glycolic acid peeling 70% in axillary and neck lesions of acanthosis nigricans: A single‐blinded, randomized trial
Background: Acanthosis nigricans is a non‐inflammatory skin pigmentary disorder characterized by a dark, velvety appearance, primarily observed in the neck and axillary areas. It is commonly associated with obesity, diabetes, and insulin resistance. Although the primary treatment is correcting the underlying disorders, many aesthetic modalities have been established to improve appearance owing to cosmetic concerns.Aims: We aimed to compare and investigate the effectiveness and side effects of tretinoin 0.05% and glycolic acid 70% in treating acanthosis nigricans lesions of the axillary and neck area.Methods: This single‐blinded, randomized trial recruited patients with neck or axillary involvement. Each patient was randomized to use cream tretinoin 0.05% every other night on one side, while the other side was treated with glycolic acid 70%, which was applied every 2 weeks at the clinic for four consecutive sessions. The study duration was 8 weeks, and patients were evaluated every 2 weeks based on their response to treatment, satisfaction, and side effects.Results: Thirty patients, including 14 with neck lesions and 16 with axillary lesions, were included. Tretinoin was significantly more effective for axillary lesions in terms of treatment response and patient satisfaction (p = 0.02 and p = 0.008, respectively). It was also shown that as the severity of the lesions increased, the response to treatment and patient satisfaction decreased, specifically when treating axillary lesions with glycolic acid (p = 0.02 and p = 0.03, respectively).Conclusion: Neither method was significantly effective for neck lesions. However, tretinoin 0.05% was shown to be more efficacious in treating axillary lesions of acanthosis nigricans, despite causing minimal side effects.
- 16 February 2024
- Published by Wiley in Journal of Cosmetic Dermatology
- Vol. 23 (6) , 2090-2096
Open AccessComparison of efficacy and safety of tretinoin 0.05% and glycolic acid peeling 70% in axillary and neck lesions of acanthosis nigricans: A single‐blinded, randomized trial
Background: Acanthosis nigricans is a non‐inflammatory skin pigmentary disorder characterized by a dark, velvety appearance, primarily observed in the neck and axillary areas. It is commonly associated with obesity, diabetes, and insulin resistance. Although the primary treatment is correcting the underlying disorders, many aesthetic modalities have been established to improve appearance owing to cosmetic concerns.Aims: We aimed to compare and investigate the effectiveness and side effects of tretinoin 0.05% and glycolic acid 70% in treating acanthosis nigricans lesions of the axillary and neck area.Methods: This single‐blinded, randomized trial recruited patients with neck or axillary involvement. Each patient was randomized to use cream tretinoin 0.05% every other night on one side, while the other side was treated with glycolic acid 70%, which was applied every 2 weeks at the clinic for four consecutive sessions. The study duration was 8 weeks, and patients were evaluated every 2 weeks based on their response to treatment, satisfaction, and side effects.Results: Thirty patients, including 14 with neck lesions and 16 with axillary lesions, were included. Tretinoin was significantly more effective for axillary lesions in terms of treatment response and patient satisfaction (p = 0.02 and p = 0.008, respectively). It was also shown that as the severity of the lesions increased, the response to treatment and patient satisfaction decreased, specifically when treating axillary lesions with glycolic acid (p = 0.02 and p = 0.03, respectively).Conclusion: Neither method was significantly effective for neck lesions. However, tretinoin 0.05% was shown to be more efficacious in treating axillary lesions of acanthosis nigricans, despite causing minimal side effects.
- Open Access
- 1 January 2024
- Published by Wiley in Dermatology Research and Practice
- Vol. 2024 (1) , 9572303
A Comparative Study of Demographic and Clinical Criteria Between Male and Female Patients With Pemphigus Referred to a Referral Hospital in Iran
Background: Pemphigus is a rare autoimmune disease characterized by the formation of blisters on the skin and mucous membranes, caused by autoantibodies against desmoglein, a key protein in cell adhesion. This study aims to compare demographic and clinical criteria between male and female patients with pemphigus referred to a referral hospital, utilizing data from the pemphigus diseases registry.Method: This retrospective cross‐sectional analysis focused on several key aspects age at disease onset, severity (measured by the Pemphigus Disease Area Index [PDAI]), types of pemphigus, duration of disease, and diagnostic criteria including the presence of antidesmoglein antibodies and findings from direct immunofluorescence (DIF). By examining these variables among a cohort selected based on their diagnosis of pemphigus, the study aimed to identify significant gender differences in disease manifestation, diagnosis, and progression. This approach is crucial for tailoring more effective gender‐specific management and treatment strategies for this rare autoimmune condition.Results: In a comprehensive analysis of 1218 pemphigus patients in the year 2021 from the hospital’s registry, comprising 543 males (44.6%) and 675 females (55.4%), significant gender differences were identified in 9 out of 44 variables examined. The study revealed that males had a higher age at disease onset, more frequent clinical manifestations in the head, neck, and trunk areas, and greater severity of disease as measured by the PDAI score compared to females. Conversely, females exhibited higher instances of mucosal manifestations and a higher PDAI score for mucosal erosion blister of the lower gingiva. No significant gender differences were found in 21 variables, including the overall age of patients, specific clinical manifestations across various mucous membranes, types of pemphigus, and PDAI scores for mucosal erosions in particular locations, indicating a nuanced gender impact on the presentation and severity of pemphigus that necessitates tailored clinical approaches.Conclusion: The study highlights significant gender differences in the presentation and severity of pemphigus, underscoring the importance of gender‐specific approaches in the diagnosis and management of this condition. The findings contribute valuable insights into the complex nature of pemphigus and underline the necessity for further research to understand the underlying mechanisms driving these differences.
- 1 January 2024
- Published by Wiley in Dermatology Research and Practice
- Vol. 2024 (1) , 9572303
Open AccessA Comparative Study of Demographic and Clinical Criteria Between Male and Female Patients With Pemphigus Referred to a Referral Hospital in Iran
Background: Pemphigus is a rare autoimmune disease characterized by the formation of blisters on the skin and mucous membranes, caused by autoantibodies against desmoglein, a key protein in cell adhesion. This study aims to compare demographic and clinical criteria between male and female patients with pemphigus referred to a referral hospital, utilizing data from the pemphigus diseases registry.Method: This retrospective cross‐sectional analysis focused on several key aspects age at disease onset, severity (measured by the Pemphigus Disease Area Index [PDAI]), types of pemphigus, duration of disease, and diagnostic criteria including the presence of antidesmoglein antibodies and findings from direct immunofluorescence (DIF). By examining these variables among a cohort selected based on their diagnosis of pemphigus, the study aimed to identify significant gender differences in disease manifestation, diagnosis, and progression. This approach is crucial for tailoring more effective gender‐specific management and treatment strategies for this rare autoimmune condition.Results: In a comprehensive analysis of 1218 pemphigus patients in the year 2021 from the hospital’s registry, comprising 543 males (44.6%) and 675 females (55.4%), significant gender differences were identified in 9 out of 44 variables examined. The study revealed that males had a higher age at disease onset, more frequent clinical manifestations in the head, neck, and trunk areas, and greater severity of disease as measured by the PDAI score compared to females. Conversely, females exhibited higher instances of mucosal manifestations and a higher PDAI score for mucosal erosion blister of the lower gingiva. No significant gender differences were found in 21 variables, including the overall age of patients, specific clinical manifestations across various mucous membranes, types of pemphigus, and PDAI scores for mucosal erosions in particular locations, indicating a nuanced gender impact on the presentation and severity of pemphigus that necessitates tailored clinical approaches.Conclusion: The study highlights significant gender differences in the presentation and severity of pemphigus, underscoring the importance of gender‐specific approaches in the diagnosis and management of this condition. The findings contribute valuable insights into the complex nature of pemphigus and underline the necessity for further research to understand the underlying mechanisms driving these differences.
- Open Access
- 9 November 2023
- Published by Oxford University Press (OUP) in Skin Health and Disease
- Vol. 3 (6) , e308
A Keratotic Nodule on a Cobblestone Plaque: A Rare Case Presentation
The manuscript describes a case of a 68-year-old woman with a pruritic nodule and yellow cobblestone plaque on her abdomen. Biopsy results showed trans epidermal illumination of basophilic elastic fibres in the reticular dermis with calcium deposits. The diagnosis was perforating calcific elastosis, an acquired rare condition mostly seen in obese, multiparous, middle-aged women.
- 9 November 2023
- Published by Oxford University Press (OUP) in Skin Health and Disease
- Vol. 3 (6) , e308
Open AccessA Keratotic Nodule on a Cobblestone Plaque: A Rare Case Presentation
The manuscript describes a case of a 68-year-old woman with a pruritic nodule and yellow cobblestone plaque on her abdomen. Biopsy results showed trans epidermal illumination of basophilic elastic fibres in the reticular dermis with calcium deposits. The diagnosis was perforating calcific elastosis, an acquired rare condition mostly seen in obese, multiparous, middle-aged women.
- Open Access
- 12 August 2023
- Published by Wiley in Journal of Cosmetic Dermatology
- Vol. 22 (11) , 2880-2888
COVID outcome in pemphigus: Does rituximab make pemphigus patients susceptible to more severe COVID‐19?
Background: The COVID‐19 pandemic has raised some concerns regarding the management of chronic skin diseases, especially in patients on immunosuppressive therapy including patients with pemphigus vulgaris (PV). Literature review reveals conflicting results about the effect of monoclonal antibodies such as rituximab on clinical outcome of COVID‐19.Objectives: To assess the reciprocal interaction of COVID‐19 and pemphigus and the effect of rituximab on prognosis of COVID‐19 in patients.Methods: We set up a retrospective study on adult patients with a confirmed diagnosis of pemphigus vulgaris and a history of COVID‐19 with or without symptoms during 2020.Results: Thirty‐six adults with pemphigus vulgaris and SARS‐CoV‐2 infection were included. The SARS‐CoV‐2 infection was confirmed with positive RT‐PCR test results in 31 cases (86.1%) and suspected in the 5 others (13.9%). Gender, total dose of rituximab, number of rituximab cycles, and involvement of head and neck were not associated to duration of COVID‐19 symptoms (p values: 0.32, 0.23, 0.84, and 0.51, respectively), severity of disease (hospitalization) (p values: 0.46, 0.39, 0.23, and 0.72, respectively), or the percentage of lung involvement on CT scan (p values: 0.07, 0.36, 0.38, and 0.09, respectively). Regarding the impact of COVID‐19 on pemphigus, the majority of patients did not experience any changes in their pemphigus regarding clinical phenotype (100%) or severity (83.3%), but PV was worsened in 6 (16.9%) patients which was controlled with increasing the prednisolone dosage.Conclusion: Rituximab appears to be safe with no increased risk of severe form of COVID‐19 in patients with pemphigus vulgaris.
- 12 August 2023
- Published by Wiley in Journal of Cosmetic Dermatology
- Vol. 22 (11) , 2880-2888
Open AccessCOVID outcome in pemphigus: Does rituximab make pemphigus patients susceptible to more severe COVID‐19?
Background: The COVID‐19 pandemic has raised some concerns regarding the management of chronic skin diseases, especially in patients on immunosuppressive therapy including patients with pemphigus vulgaris (PV). Literature review reveals conflicting results about the effect of monoclonal antibodies such as rituximab on clinical outcome of COVID‐19.Objectives: To assess the reciprocal interaction of COVID‐19 and pemphigus and the effect of rituximab on prognosis of COVID‐19 in patients.Methods: We set up a retrospective study on adult patients with a confirmed diagnosis of pemphigus vulgaris and a history of COVID‐19 with or without symptoms during 2020.Results: Thirty‐six adults with pemphigus vulgaris and SARS‐CoV‐2 infection were included. The SARS‐CoV‐2 infection was confirmed with positive RT‐PCR test results in 31 cases (86.1%) and suspected in the 5 others (13.9%). Gender, total dose of rituximab, number of rituximab cycles, and involvement of head and neck were not associated to duration of COVID‐19 symptoms (p values: 0.32, 0.23, 0.84, and 0.51, respectively), severity of disease (hospitalization) (p values: 0.46, 0.39, 0.23, and 0.72, respectively), or the percentage of lung involvement on CT scan (p values: 0.07, 0.36, 0.38, and 0.09, respectively). Regarding the impact of COVID‐19 on pemphigus, the majority of patients did not experience any changes in their pemphigus regarding clinical phenotype (100%) or severity (83.3%), but PV was worsened in 6 (16.9%) patients which was controlled with increasing the prednisolone dosage.Conclusion: Rituximab appears to be safe with no increased risk of severe form of COVID‐19 in patients with pemphigus vulgaris.
- Open Access
- 22 November 2022
- Published by S. Karger AG in Case Reports in Dermatology
- Vol. 14 (3) , 350-355
Dipeptidyl-Peptidase 4 Inhibitor-Induced Variants of Bullous Pemphigoid: A Case Series of Four Patients
Bullous pemphigoid is the most common acquired bullous disease with an autoimmune basis and a tendency to involve mostly old people. By rising incidence of diabetes all over the world, consumption of antidiabetes medications has also increased. One of the most used antidiabetes drugs is gliptin family (dipeptidyl-peptidase 4 inhibitor). Recently, this class of oral antidiabetic agents showed a correlation with the occurrence of bullous pemphigoid and its subtypes, including mucous membrane pemphigoid and pemphigoid nodularis. We are reporting a case series of 4 diabetes patients that we diagnosed with bullous pemphigoid subtypes (mucous membrane pemphigoid, pemphigoid nodularis, and its rarest subtype, linear IgA bullous dermatosis) after taking different drugs of gliptin family.
- 22 November 2022
- Published by S. Karger AG in Case Reports in Dermatology
- Vol. 14 (3) , 350-355
Open AccessDipeptidyl-Peptidase 4 Inhibitor-Induced Variants of Bullous Pemphigoid: A Case Series of Four Patients
Bullous pemphigoid is the most common acquired bullous disease with an autoimmune basis and a tendency to involve mostly old people. By rising incidence of diabetes all over the world, consumption of antidiabetes medications has also increased. One of the most used antidiabetes drugs is gliptin family (dipeptidyl-peptidase 4 inhibitor). Recently, this class of oral antidiabetic agents showed a correlation with the occurrence of bullous pemphigoid and its subtypes, including mucous membrane pemphigoid and pemphigoid nodularis. We are reporting a case series of 4 diabetes patients that we diagnosed with bullous pemphigoid subtypes (mucous membrane pemphigoid, pemphigoid nodularis, and its rarest subtype, linear IgA bullous dermatosis) after taking different drugs of gliptin family.
- 4 July 2022
- Published by Wiley in Dermatologic Therapy
- Vol. 35 (8) , e15651
Cutaneous manifestations following COVID‐19 vaccination: A report of 25 cases
Various adverse effects particularly cutaneous manifestations associated with different COVID‐19 vaccines have been observed in practice. The aim of our study was to evaluate all patients who presented to our tertiary center with skin manifestations following COVID‐19 vaccines injection from September to December 2021. All patients with skin manifestation within 30 days or less following COVID‐19 vaccination were enrolled in our case‐series. All cases included in our study were diagnosed based on clinical and/or histopathological evaluation and all other possible differential diagnoses were ruled out. Twenty‐five individuals including 16 (64%) males and 9 (36%) females with the mean age of 47 ± 17.62 years (range 18–91) were enrolled in our study. Twenty‐two (88%) patients developed lesions after Sinopharm vaccine injection and 3 (12%) cases manifested lesions after the AstraZeneca vaccine. Six (24%) patients developed new‐onset lichen planus (LP) and 1 (4%) patient manifested LP flare‐up. Two (8%) individuals developed psoriasis and 1 (4%) case showed psoriasis exacerbation. One (4%) patient developed new‐onset pemphigus vulgaris (PV) and 1 (4%) case experienced a flare of PV lesions. One (4%) patient manifested pityriasis lichenoides et varioliformis acuta (PLEVA) flare‐up. Other new‐onset cases were as follows: toxic epidermal necrolysis (TEN) (n = 1, 4%), bullous pemphigoid (BP) (n = 2, 8%), alopecia areata (AA) (n = 2, 8%), pytriasis rosea (n = 1, 4%), herpes zoster (n = 1, 4%), cutaneous small vessel vasculitis (n = 1, 4%), erythema multiform (EM) and urticaria (n = 3, 12%), and morphea (n = 1, 4%). Physicians should be aware of the possible side effects especially cutaneous manifestations associated with COVID‐19 vaccines.
- 4 July 2022
- Published by Wiley in Dermatologic Therapy
- Vol. 35 (8) , e15651
Cutaneous manifestations following COVID‐19 vaccination: A report of 25 cases
Various adverse effects particularly cutaneous manifestations associated with different COVID‐19 vaccines have been observed in practice. The aim of our study was to evaluate all patients who presented to our tertiary center with skin manifestations following COVID‐19 vaccines injection from September to December 2021. All patients with skin manifestation within 30 days or less following COVID‐19 vaccination were enrolled in our case‐series. All cases included in our study were diagnosed based on clinical and/or histopathological evaluation and all other possible differential diagnoses were ruled out. Twenty‐five individuals including 16 (64%) males and 9 (36%) females with the mean age of 47 ± 17.62 years (range 18–91) were enrolled in our study. Twenty‐two (88%) patients developed lesions after Sinopharm vaccine injection and 3 (12%) cases manifested lesions after the AstraZeneca vaccine. Six (24%) patients developed new‐onset lichen planus (LP) and 1 (4%) patient manifested LP flare‐up. Two (8%) individuals developed psoriasis and 1 (4%) case showed psoriasis exacerbation. One (4%) patient developed new‐onset pemphigus vulgaris (PV) and 1 (4%) case experienced a flare of PV lesions. One (4%) patient manifested pityriasis lichenoides et varioliformis acuta (PLEVA) flare‐up. Other new‐onset cases were as follows: toxic epidermal necrolysis (TEN) (n = 1, 4%), bullous pemphigoid (BP) (n = 2, 8%), alopecia areata (AA) (n = 2, 8%), pytriasis rosea (n = 1, 4%), herpes zoster (n = 1, 4%), cutaneous small vessel vasculitis (n = 1, 4%), erythema multiform (EM) and urticaria (n = 3, 12%), and morphea (n = 1, 4%). Physicians should be aware of the possible side effects especially cutaneous manifestations associated with COVID‐19 vaccines.